Media coverage about BioDelivery Sciences International (NASDAQ:BDSI) has trended somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioDelivery Sciences International earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 44.730276153439 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have impacted Accern’s rankings:
- BioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher – Nasdaq (nasdaq.com)
- Blog Exposure – Dova Pharma Inked Agreement with Fosun Pharma for Distribution of Avatrombopag in Mainland China and Hong Kong (finance.yahoo.com)
- BioDelivery Sciences International (BDSI) Given a $4.00 Price Target by HC Wainwright Analysts (americanbankingnews.com)
- William Blair Comments on BioDelivery Sciences International, Inc.’s Q1 2019 Earnings (BDSI) (americanbankingnews.com)
Shares of BioDelivery Sciences International stock opened at $2.10 on Thursday. The company has a quick ratio of 1.29, a current ratio of 1.52 and a debt-to-equity ratio of 5.37. The stock has a market capitalization of $113.98, a P/E ratio of -11.05 and a beta of 0.51. BioDelivery Sciences International has a twelve month low of $1.55 and a twelve month high of $3.60.
Several brokerages have issued reports on BDSI. HC Wainwright set a $4.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Monday. Zacks Investment Research upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Wednesday, February 14th. ValuEngine lowered BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Seaport Global Securities began coverage on BioDelivery Sciences International in a research report on Friday, January 26th. They set a “buy” rating and a $5.00 target price for the company. Finally, Cantor Fitzgerald restated a “buy” rating and set a $5.00 target price on shares of BioDelivery Sciences International in a research report on Thursday, March 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $4.25.
In related news, Director Francis E. Odonnell, Jr. sold 113,876 shares of the business’s stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $2.14, for a total value of $243,694.64. Following the completion of the transaction, the director now owns 319,717 shares of the company’s stock, valued at $684,194.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mark A. Sirgo sold 108,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $2.57, for a total transaction of $277,560.00. Following the completion of the transaction, the director now directly owns 1,759,262 shares of the company’s stock, valued at approximately $4,521,303.34. The disclosure for this sale can be found here. Insiders sold 1,093,887 shares of company stock valued at $2,909,970 in the last quarter. 7.73% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/22/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-biodelivery-sciences-international-bdsi-share-price/1926135.html.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.